An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

In addition, AstraZeneca’s experimental cholesterol drug AZD0780 showed promising results in a Phase IIb clinical trial by significantly reducing LDL-C levels in patients. The trial results were ...

Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

At 12 weeks, AZD0780 30mg taken once-daily led to a 50.7% reduction in LDL-C. Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin ...

Upbeat Data From AZN’s Phase II Cholesterol Drug Study AstraZeneca presented positive data from a mid-stage study of its investigational once-daily oral PCSK9 inhibitor, AZD0780, at the annual ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol (LDL-C). It acts as a small molecule inhibitor of proprotein ...

The drug, which goes by the name AZD0780, inhibits a protein called PCSK9. Merck & Co. has a competing medicine in development targeting the same protein. Merck’s drug resulted in a reduction of ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...